<p>西氏医药服务（NYSE:WST - 获取免费报告）宣布其董事会于 2 月 17 日星期二启动了一项股票回购计划，RTT News 报道。该公司计划回购 10 亿美元的流通股。这项回购授权允许这家医疗器械供应商通过公开市场购买最多 5.6% 的股票。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
<h2>西氏医药服务股票下跌 2.9%</h2>
<ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
<p>在星期二的午盘交易中，NYSE WST 的股票下跌了 7.22 美元，达到 243.27 美元。该公司交易了 969,895 股，而其平均交易量为 1,265,581 股。西氏医药服务的 1 年最低价为 187.43 美元，1 年最高价为 322.34 美元。该公司的 50 日移动平均为 260.12 美元，200 日移动平均为 261.81 美元。该股票的市值为 175 亿美元，市盈率为 35.83，市盈增长比率为 3.27，贝塔值为 1.18。该公司的速动比率为 2.34，流动比率为 3.02，债务股本比率为 0.06。</p>
<p>西氏医药服务（NYSE:WST - 获取免费报告）最近一次公布财报是在 2 月 12 日星期四。这家医疗器械供应商报告本季度每股收益为 2.04 美元，超出分析师一致预期的 1.83 美元，超出幅度为 0.21 美元。西氏医药服务的净利润率为 16.06%，股本回报率为 17.90%。该公司本季度的收入为 8.05 亿美元，而一致预期为 7.957 亿美元。在去年同期，该公司的每股收益为 1.82 美元。该公司的收入同比增长了 7.5%。西氏医药服务已将其 2026 财年的指导目标设定为每股收益 7.850-8.200 美元。研究分析师平均预计西氏医药服务在当前年度的每股收益为 6.62 美元。</p>
<h2>西氏医药服务宣布分红</h2>
<ul>
<li>今年哪些因素将推动标普 500 表现？</li>
</ul>
<p>该公司最近还宣布了一项季度分红，已于 2 月 4 日星期三支付。1 月 28 日星期三的股东获得了 0.22 美元的分红。除息日期为 1 月 28 日星期三。这相当于年化分红为 0.88 美元，收益率为 0.4%。西氏医药服务的分红支付比率（DPR）为 12.96%。</p>
<h2>华尔街分析师的看法</h2>
<p>几位股票研究分析师最近对该股票发表了看法。Evercore 将西氏医药服务的目标股价从 390.00 美元下调至 320.00 美元，并在 2 月 3 日的研究报告中给予该股票 “跑赢大盘” 的评级。巴克莱将西氏医药服务的目标股价从 325.00 美元下调至 265.00 美元，并在周五的报告中给予该公司 “持平” 的评级。Weiss Ratings 在 1 月 9 日的报告中重申了对西氏医药服务的 “持有（c）” 评级。杰富瑞金融集团在 2 月 10 日的研究报告中重新发布了 “买入” 评级，并对西氏医药服务的股票设定了 295.00 美元的目标价。最后，瑞银集团在周五的研究报告中重申了 “买入” 评级，并将西氏医药服务的目标股价设定为 340.00 美元。三位分析师对该股票给予了强烈买入评级，七位给予了买入评级，三位对该公司的股票给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价为 314.56 美元。</p>
<ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
<p><strong>查看我们最新的 WST 股票分析</strong></p>
<h2>西氏医药服务公司简介</h2>
<p>获取免费报告）</p>
<p>西氏医药服务公司是一家全球开发和制造组件、系统及服务的公司，旨在实现可注射药物的封装和输送。该公司专注于为制药和生物技术行业提供高质量的包装和输送解决方案，生产用于疫苗、生物制剂和其他可注射疗法的主要药物包装组件和专用药物输送设备。西氏以其保持无菌性和与敏感药物配方兼容的弹性密封件、密封和聚合物组件而闻名。</p>
<p>除了组件制造外，西氏还提供工程化输送系统和产品生命周期支持服务。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票比西氏医药服务更好</li>
<li>你的银行账户不再安全</li>
<li>Nvidia CEO 发出大胆的特斯拉呼吁</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在西氏医药服务吗？</h2>
<p>在你考虑西氏医药服务之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而西氏医药服务并不在名单上。</p>
<p>虽然西氏医药服务目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

纽交所高增长板生物技术指数 ETF - First Trust

美国医药设备 ETF - iShares

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

标普健康医疗设备 ETF - SPDR

西氏医药服务

标普生物技术 ETF - SPDR

<p>西氏医药服务（NYSE:WST）宣布了一项 10 亿美元的股票回购计划，允许公司回购最多 5.6% 的流通股。这一决定反映了董事会对股票被低估的信心。该公司的股票最近下跌了 2.9%，报 243.27 美元，市值为 175 亿美元。西氏报告的季度每股收益为 2.04 美元，超出预期，并已将 2026 财年的指导目标设定为每股收益 7.850-8.200 美元。分析师对该股票的评级不一，平均目标价为 314.56 美元</p>

<p>West Pharmaceutical Services (NYSE:WST - Get Free Report) announced that its board has initiated a stock repurchase plan on Tuesday, February 17th, RTT News reports. The company plans to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy up to 5.6% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board of directors believes its stock is undervalued.</p>
<div class="lb-trans"><p>西氏医药服务（NYSE:WST - 获取免费报告）宣布其董事会于 2 月 17 日星期二启动了一项股票回购计划，RTT News 报道。该公司计划回购 10 亿美元的流通股。这项回购授权允许这家医疗器械供应商通过公开市场购买最多 5.6% 的股票。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
</div><h2>West Pharmaceutical Services Stock Down 2.9%</h2>
<div class="lb-trans"><h2>西氏医药服务股票下跌 2.9%</h2>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
</div><p>Shares of NYSE WST traded down $7.22 during mid-day trading on Tuesday, reaching $243.27. 969,895 shares of the company were exchanged, compared to its average volume of 1,265,581. West Pharmaceutical Services has a 1 year low of $187.43 and a 1 year high of $322.34. The firm has a 50-day moving average of $260.12 and a 200 day moving average of $261.81. The stock has a market cap of $17.50 billion, a price-to-earnings ratio of 35.83, a P/E/G ratio of 3.27 and a beta of 1.18. The company has a quick ratio of 2.34, a current ratio of 3.02 and a debt-to-equity ratio of 0.06.</p>
<div class="lb-trans"><p>在星期二的午盘交易中，NYSE WST 的股票下跌了 7.22 美元，达到 243.27 美元。该公司交易了 969,895 股，而其平均交易量为 1,265,581 股。西氏医药服务的 1 年最低价为 187.43 美元，1 年最高价为 322.34 美元。该公司的 50 日移动平均为 260.12 美元，200 日移动平均为 261.81 美元。该股票的市值为 175 亿美元，市盈率为 35.83，市盈增长比率为 3.27，贝塔值为 1.18。该公司的速动比率为 2.34，流动比率为 3.02，债务股本比率为 0.06。</p>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last announced its earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.83 by $0.21. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The business had revenue of $805.00 million during the quarter, compared to the consensus estimate of $795.70 million. During the same period in the previous year, the company posted $1.82 earnings per share. The firm's revenue was up 7.5% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. On average, research analysts expect that West Pharmaceutical Services will post 6.62 earnings per share for the current year.</p>
<div class="lb-trans"><p>西氏医药服务（NYSE:WST - 获取免费报告）最近一次公布财报是在 2 月 12 日星期四。这家医疗器械供应商报告本季度每股收益为 2.04 美元，超出分析师一致预期的 1.83 美元，超出幅度为 0.21 美元。西氏医药服务的净利润率为 16.06%，股本回报率为 17.90%。该公司本季度的收入为 8.05 亿美元，而一致预期为 7.957 亿美元。在去年同期，该公司的每股收益为 1.82 美元。该公司的收入同比增长了 7.5%。西氏医药服务已将其 2026 财年的指导目标设定为每股收益 7.850-8.200 美元。研究分析师平均预计西氏医药服务在当前年度的每股收益为 6.62 美元。</p>
</div><h2>West Pharmaceutical Services Announces Dividend</h2>
<div class="lb-trans"><h2>西氏医药服务宣布分红</h2>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年哪些因素将推动标普 500 表现？</li>
</ul>
</div><p>The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 4th. Shareholders of record on Wednesday, January 28th were paid a $0.22 dividend. The ex-dividend date was Wednesday, January 28th. This represents a $0.88 dividend on an annualized basis and a yield of 0.4%. West Pharmaceutical Services's dividend payout ratio (DPR) is 12.96%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，已于 2 月 4 日星期三支付。1 月 28 日星期三的股东获得了 0.22 美元的分红。除息日期为 1 月 28 日星期三。这相当于年化分红为 0.88 美元，收益率为 0.4%。西氏医药服务的分红支付比率（DPR）为 12.96%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>Several equities research analysts recently weighed in on the stock. Evercore reduced their price target on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an &#34;outperform&#34; rating on the stock in a research report on Tuesday, February 3rd. Barclays lowered their target price on shares of West Pharmaceutical Services from $325.00 to $265.00 and set an &#34;equal weight&#34; rating for the company in a report on Friday. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of West Pharmaceutical Services in a report on Friday, January 9th. Jefferies Financial Group reissued a &#34;buy&#34; rating and issued a $295.00 price objective on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Finally, UBS Group restated a &#34;buy&#34; rating and set a $340.00 target price on shares of West Pharmaceutical Services in a research report on Friday. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Buy&#34; and an average price target of $314.56.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该股票发表了看法。Evercore 将西氏医药服务的目标股价从 390.00 美元下调至 320.00 美元，并在 2 月 3 日的研究报告中给予该股票 “跑赢大盘” 的评级。巴克莱将西氏医药服务的目标股价从 325.00 美元下调至 265.00 美元，并在周五的报告中给予该公司 “持平” 的评级。Weiss Ratings 在 1 月 9 日的报告中重申了对西氏医药服务的 “持有（c）” 评级。杰富瑞金融集团在 2 月 10 日的研究报告中重新发布了 “买入” 评级，并对西氏医药服务的股票设定了 295.00 美元的目标价。最后，瑞银集团在周五的研究报告中重申了 “买入” 评级，并将西氏医药服务的目标股价设定为 340.00 美元。三位分析师对该股票给予了强烈买入评级，七位给予了买入评级，三位对该公司的股票给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价为 314.56 美元。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
</div><p><strong>View Our Latest Stock Analysis on WST</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 WST 股票分析</strong></p>
</div><h2>West Pharmaceutical Services Company Profile</h2>
<div class="lb-trans"><h2>西氏医药服务公司简介</h2>
</div><p>Get Free Report)</p>
<div class="lb-trans"><p>获取免费报告）</p>
</div><p>West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.</p>
<div class="lb-trans"><p>西氏医药服务公司是一家全球开发和制造组件、系统及服务的公司，旨在实现可注射药物的封装和输送。该公司专注于为制药和生物技术行业提供高质量的包装和输送解决方案，生产用于疫苗、生物制剂和其他可注射疗法的主要药物包装组件和专用药物输送设备。西氏以其保持无菌性和与敏感药物配方兼容的弹性密封件、密封和聚合物组件而闻名。</p>
</div><p>In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.</p>
<div class="lb-trans"><p>除了组件制造外，西氏还提供工程化输送系统和产品生命周期支持服务。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Nvidia CEO Issues Bold Tesla Call</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比西氏医药服务更好</li>
<li>你的银行账户不再安全</li>
<li>Nvidia CEO 发出大胆的特斯拉呼吁</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在西氏医药服务吗？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑西氏医药服务之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而西氏医药服务并不在名单上。</p>
</div><p>While West Pharmaceutical Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然西氏医药服务目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

West Pharmaceutical Services (NYSE:WST) to Buyback $1.00 billion in  Outstanding Shares

Market Beat

西氏医药服务（NYSE:WST）将回购价值 10 亿美元的流通股